U.S., Oct. 1 -- ClinicalTrials.gov registry received information related to the study (NCT07198958) titled 'Immune Adverse Events Registry in Onco-Hematologic Patients Treated With Immunotherapy' on Sept. 15.
Brief Summary: Immunotherapy is a therapeutic strategy aimed at inducing the immune system to identify and combat cancer cells and, alongside the evident clinical success observed in many patients, a specific toxicity profile has emerged, associated with the modulation of the immune system achieved with this type of drugs, known as Immune-Related Adverse Events (irAEs). irAEs encompass a highly heterogeneous spectrum of autoimmune manifestations that can potentially involve any organ or system, occurring in ~ 80% of patients treated w...